2020 Adi F. Gazdar IASLC Merit Award Recipient: Dr. Alex A. Adjei

Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey 

Benefit to Pembrolizumab Observed in Previously Treated Malignant Pleural Mesothelioma Irrespective of PD-L1 Status

Treatment of Immunotherapy-Related Ophthalmic Toxicities: An Interview With Dr. Asim V. Farooq

Understanding and Targeting SCLC

KRAS: Old Target, New Hope

Molecular Resistance Mechanisms to EGFR, ALK, and ROS1 TKIs

Approval of Combination Ipilimumab and Nivolumab for Mesothelioma: What Happens Now?

Mutation or Amplification: Who MET the Expectations?

RET Therapy for NSCLC, a New Generation of Inhibitors

The Multitude of Options for First-Line Therapy for EGFR-Mutated Lung Cancer

The Current Role of Combination Maintenance Therapy (Pemetrexed and Bevacizumab) in the Era of Immunotherapy